Snakebites: costing recombinant antivenoms

Journal name:
Date published:
Published online

The cost of producing antivenoms from recombinant human antibodies to counter the shortage of animal-derived antisera against snakebites is not as prohibitive as you imply (Nature 537, 2628; 2016).

We estimate that 500–2,000 kilograms of therapeutically active antibodies would be needed to produce enough antivenom to treat the 1 million or so people bitten annually by snakes in sub-Saharan Africa. On the basis of production data for monoclonal antibodies (N. Hammerschmidt et al. Biotechnol. J. 9, 766775; 2014) and for oligoclonal antibody mixtures (S. K. Rasmussen et al. Arch. Biochem. Biophys. 526, 139145; 2012), we calculate that antivenoms created from a mixture of recombinant antibodies could be produced on this scale for US$55–65 per gram.

A typical African snakebite could therefore be treated with a pan-African recombinant-antibody antivenom for $30–150. This compares favourably with the wholesale cost of a typical dose of conventional antiserum ($60–600, which includes packaging and transport, as well as production, costs).

Author information

  1. *On behalf of 4 correspondents (see Supplementary information for full list).

    • Andreas H. Laustsen


  1. Technical University of Denmark, Lyngby, Denmark.

    • Andreas H. Laustsen

Corresponding author

Correspondence to:

Author details

Supplementary information

Additional data